2012-10-19 09:05:58 - AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 - a new market research report on companiesandmarkets.com

AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020 - GlobalData´s pharmaceuticals report, "AMG 386 (Ovarian Cancer) - Analysis and Forecasts to 2020" provides AMG 386 sales forecasts for the US, EU and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2015-2020). The report also includes information on Ovarian Cancer market. This report is built using data and information sourced from GlobalData´s proprietary databases, primary and secondary research using Company´s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData´s team of industry experts.

Report Scope

- Therapy

 

 

area profile including patient population for the US, EU and Japan (seven major markets)
- Analysis and review of AMG 386 including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of AMG 386 including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2015-2020 for AMG 386 in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug´s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

AMG 386, ovarian cancer, recombinant Fc-peptide fusion protein, Amgen, first-in-class investigational peptibody , vascular endothelial growth factors (VEGFs), sales forecast, phase III/pipeline, competitors to AMG 386 Farletuzumab, Yondelis, Hexalen, Avastin, Gemzar, gemcitabine, farletuzumab

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.